OncoDaily IO shared a post on LinkedIn:
“Top Immunotherapy Trials – ESMO GI 2025 Highlights.
1. MATTERHORN (Phase III): Durvalumab + FLOT in resectable gastric/GEJ cancer
- 29% EFS risk reduction (HR 0.71, p<0.001)
- FDA Priority Review granted
2. SIERRA (Phase 3b): Durvalumab + Tremelimumab (STRIDE) in advanced HCC with poor-risk features
- Safe and feasible in CP B7/B8, ECOG 2, Vp4 patients
3. EXPEL PANC (Phase II): BXCL701 + Pembrolizumab in 2L pancreatic cancer
- DCR: 39%, PR: 17% – early signals in an immune-cold tumor
4, ABSK-011-201 (Phase II): Irpagratinib + Atezolizumab in FGF19+ HCC
- ORR >50%, mPFS ≥7mo – encouraging in biomarker-driven population
5, Givastomig Trial (Phase I/II): CLDN18.2/4-1BB bispecific + Nivo + FOLFOX in mGEC
- ORR 71%, effective even in low PD-L1/CLDN18.2 settings
These trials reflect real innovation – targeted, biomarker-driven, and inclusive of hard-to-treat GI cancers.”